Business Wire

Ushering in a New Era of Medical Education at NTHU

2.10.2021 08:00:00 EEST | Business Wire | Press release

Share

National Tsing Hua University’s plan to establish a post-baccalaureate program in medicine has been approved at a recent cross-ministerial meeting held at the Ministry of Education. The school’s recruitment and admission application process will begin by the end of 2021, and the first class of government-sponsored students will be enrolled in September 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211001005043/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

College of Life Science dean Kao Ruey-Ho (left) and Department of Medical Science chair Chen Linyi (right) prepare for the post-baccalaureate program in medicine. (Photo: National Tsing Hua University)

NTHU President Hocheng Hong said that NTHU already has a strong foundation in cross-disciplinary research in medical science, including big data analysis, application of artificial intelligence (AI), bioengineering, material science, and nuclear medicine, by which the school is well-positioned to train physicians specializing in more than one expertise. As such, this new program represents a quantum jump in medical education in Taiwan.

President Hocheng said that NTHU already has sufficient number of faculty members, funding, and infrastructure for the new program. In addition to the existing 180 faculty members teaching related courses, the program has recently recruited an additional 71 full-time faculty members, and 87 physician scientists from leading medical centers throughout Taiwan as adjunct faculty members. Moreover, the provisional office of this program has raised NT$2 billion for medical education. An ongoing plan for establishing a state-of-the-art teaching hospital and medical complex in the Taoyuan Aerotropolis next to the Taoyuan International Airport is currently being reviewed by the Ministry of Health and Welfare.

The post-baccalaureate program in medicine is a four-year program, open for graduates from all disciplines. The government-sponsored students will be required to serve in a public healthcare facility for six years. They will have an opportunity to undertake an additional two years of advanced training in a medical center.

NTHU will draw on its extensive experience in student recruitment to admit only those applicants who meet the stringent admission qualifications, the innovative student selection process could open a new path for medical education in Taiwan.

The post-baccalaureate program in medicine will be part of the future College of Life Sciences and Medicine (currently the College of Life Science). Dean of the College of Life Science, Kao Ruey-Ho, former Superintendent of Tzu Chi Medical Center, said that applicants who apply directly to NTHU will be evaluated based on test scores, transcripts, and interviews, to select students who have demonstrated academic excellence, as well as a passion for medicine and public welfare.

Government-sponsored students in the program will take several courses designed to prepare them for practicing in a rural area, such as Community Medicine Practicum, and make good use of AI diagnosis and telemedicine technology; they will also attend seminars on altruism and dedication to public health, which will be taught by laureates of the Medical Contribution Award.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Holly Hsueh
NTHU
(886)3-5162006
hoyu@mx.nthu.edu.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol

MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 16:36:00 EEST | Press release

MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going on to establish LavaFX and Ogg Trading. His career has also incl

Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 16:00:00 EEST | Press release

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction Transactions Debt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance to $43.4 million. Share Repurchases: The Company repurchased 970,566 shares of its common stock at an average price of $5.16 per share for an aggregate cost of approximately $5.0 million. “Our year-to-date share repurchases

rhode Announces Official Launch Date for Its Retail Expansion in Europe with Sephora31.8.2026 16:00:00 EEST | Press release

rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), today announced its collection of high-performance, skin-focused products will be available at Sephora online and in most stores across Europe starting Wednesday, 30 September, 2026, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831869746/en/ rhode will be available at Sephora online and in most stores across Europe starting Wednesday, 30 September, 2026 Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode remains the No.1 overall skincare

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye